Equities

Santen Pharmaceutical Co Ltd

Santen Pharmaceutical Co Ltd

Actions
  • Price (EUR)10.90
  • Today's Change-0.300 / -2.68%
  • Shares traded0.00
  • 1 Year change+22.47%
  • Beta--
Data delayed at least 15 minutes, as of Sep 18 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments94,96158,67784,307
Total Receivables, Net90,539107,22599,591
Total Inventory43,18539,35237,141
Prepaid expenses------
Other current assets, total7,4548,0728,387
Total current assets236,139213,326229,426
Property, plant & equipment, net71,57666,17356,287
Goodwill, net8,3037,38513,715
Intangibles, net75,51688,924116,502
Long term investments24,40637,35936,238
Note receivable - long term------
Other long term assets1,8291,7641,694
Total assets435,699421,179459,976
LIABILITIES
Accounts payable24,04225,28224,420
Accrued expenses------
Notes payable/short-term debt000
Current portion long-term debt/capital leases2,7483,05613,965
Other current liabilities, total66,00661,16657,436
Total current liabilities92,79689,50495,821
Total long term debt31,86233,15118,967
Total debt34,61036,20732,932
Deferred income tax1,3771,5922,526
Minority interest(685)(683)(645)
Other liabilities, total4,2953,6355,818
Total liabilities129,645127,199122,487
SHAREHOLDERS EQUITY
Common stock8,7778,7028,672
Additional paid-in capital9,8549,7899,370
Retained earnings (accumulated deficit)240,210238,402290,861
Treasury stock - common(1018)(364)(718)
Unrealized gain (loss)5,4817,9178,438
Other equity, total42,75029,53420,866
Total equity306,054293,980337,489
Total liabilities & shareholders' equity435,699421,179459,976
Total common shares outstanding363376400
Treasury shares - common primary issue0.790.350.42
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.